Literature DB >> 18978559

Diagnostic and prognostic implications of pleural adhesions in malignant effusions.

Silvia Bielsa1, José Martín-Juan, José M Porcel, Francisco Rodríguez-Panadero.   

Abstract

BACKGROUND AND
OBJECTIVE: We aimed to examine the frequency of pleural adhesions and to determine their relationship with pleural tumor burden, pleural fluid (PF) biochemistries, PF cytologic yield, and survival in patients with malignant pleural effusion (MPE).
METHODS: We performed retrospective analysis of 540 consecutive patients with MPE who underwent medical thoracoscopy. Pleural lesion rating and grade of pleural adhesions based on a thoracoscopic score model were recorded.
RESULTS: Sixty percent of patients with MPE were found to have adhesions in the pleural space. The sensitivity of PF cytology was 71% if there were no pleural adhesions, and 20% if the maximum adhesion score was reached (p < 0.01). The extent of pleural adhesions correlated positively with the pleural tumor burden, and inversely with PF pH. The median survival of patients with minimal or no adhesions in the pleural space was 9 months as compared with patients with the highest grade of adhesions, whose median survival was 5 months (p < 0.01).
CONCLUSION: MPE are often loculated. The higher the grade of pleural adhesions, the greater the tumor burden exists, and paradoxically the lower the PF cytologic yield. The presence of pleural adhesions in MPE implies a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18978559     DOI: 10.1097/JTO.0b013e318189f53d

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  12 in total

Review 1.  Current best practice in the evaluation and management of malignant pleural effusions.

Authors:  Steven Walker; Anna C Bibby; Nick A Maskell
Journal:  Ther Adv Respir Dis       Date:  2016-10-24       Impact factor: 4.031

Review 2.  Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.

Authors:  Seiki Hasegawa; Nobuyuki Kondo; Seiji Matsumoto; Teruhisa Takuwa; Masaki Hashimoto; Hayato Orui; Shunichi Fukuda; Kazue Yoneda; Yoshitomo Okumura; Noriaki Tsubota; Kazuya Fukuoka; Ikuko Torii; Tohru Tsujimura; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

Review 3.  Malignant pleural effusions: appropriate treatment approaches.

Authors:  Yener Aydin; Atila Turkyilmaz; Yavuz Selim Intepe; Atilla Eroglu
Journal:  Eurasian J Med       Date:  2009-12

4.  Diagnostic value and safety of medical thoracoscopy for pleural effusion of different causes.

Authors:  Xiao-Ting Liu; Xi-Lin Dong; Yu Zhang; Ping Fang; Hong-Yang Shi; Zong-Juan Ming
Journal:  World J Clin Cases       Date:  2022-04-06       Impact factor: 1.534

Review 5.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

6.  The importance of serum and pleural fluid level of vascular endothelial growth factor (VEGF) and VEGF fluid/serum ratio in the differential diagnosis of malignant mesothelioma-related pleural effusion.

Authors:  Yakup Düzköprü; Zeynep Oruç; Muhammet A Kaplan; Refik Ülkü; Çetin Tanrıkulu; Derya Esmer; Ali Bırak; Mehmet Küçüköner; Zuhat Urakçı; Abdurrahman Işıkdoğan
Journal:  Contemp Oncol (Pozn)       Date:  2017-09-29

7.  Medical Thoracoscopy in Pleural Disease: Experience from a One-Center Study.

Authors:  Soo Jung Kim; Sun Mi Choi; Jinwoo Lee; Chang-Hoon Lee; Sang-Min Lee; Jae-Joon Yim; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Young Sik Park
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-03-31

Review 8.  Management of Septated Malignant Pleural Effusions.

Authors:  Radhika Banka; Dayle Terrington; Eleanor K Mishra
Journal:  Curr Pulmonol Rep       Date:  2018-01-20

9.  Predictors of survival in non-small cell lung cancer patients with pleural effusion undergoing thoracoscopy.

Authors:  Li-Xu Xie; Xing-Guang Wang; Wen-Jie You; Xiao-Bin Ma; Yong-Gang Wang; Ting-Ting Liu; Shu-Juan Jiang
Journal:  Thorac Cancer       Date:  2019-05-15       Impact factor: 3.500

10.  In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening.

Authors:  Cheng-Guang Wu; Francesca Chiovaro; Alessandra Curioni-Fontecedro; Ruben Casanova; Alex Soltermann
Journal:  J Transl Med       Date:  2020-04-10       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.